Widespread vaccination is a principal strategy to mitigate the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lessen the global burden of coronavirus disease 2019 (COVID-19). Information is rapidly evolving about the impact of SARS-CoV-2 vaccines on the immune and endocrine systems. This case series heightens clinical awareness of possible thyroid effects and conveys knowledge of what to monitor, which are fundamental components of public health and pharmacovigilance. We present a case series of Graves disease following mRNA SARS-CoV-2 vaccination, with symptoms and altered thyroid function tests developing within 7 days of the first dose in 2 women aged 38 and 63 years, and 28 days after the second dose in a 30-year-old man. New-onset Graves disease occurred following administration of mRNA vaccines against SARS-CoV-2. Based on the timing of signs and symptoms relative to administration of the vaccine and the absence of other probable causes, we consider the vaccine as a potential contributor to the diagnosis. The viral spike protein, delivered indirectly through an encoded mRNA vaccine, may be capable of triggering an inflammatory cascade and immune response triggering thyroid dysfunction.

1. Murugan, AK, Alzahrani, AS. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease. Endocrine. 2021;73:243-254. doi:10.1007/s12020-021-02770-6.
Google Scholar | Crossref | Medline2. Vera-Lastra, O, Ordinola Navarro, A, Cruz Domiguez, MP, Medina, G, Sánchez Valadez, TI, Jara, LJ. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021; 31:1436-1439. doi:10.1089/thy.2021.0142.
Google Scholar | Crossref | Medline3. Zettinig, G, Krebs, M. Two further cases of Graves’ disease following SARS-Cov-2 vaccination. J Endocrinol Invest. 2021. doi:10.1007/s40618-021-01650-0.
Google Scholar | Crossref4. Sriphrapradang, C. Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease. Endocrine. 2021;74:226-227. doi:10.1007/s12020-021-02879-8.
Google Scholar | Crossref | Medline5. Mateu-Salat, M, Urgell, E, Chico, A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest. 2020;43:1527-1528. doi:10.1007/s40618-020-01366-7.
Google Scholar | Crossref | Medline6. Chen, W, Tian, Y, Li, Z, Zhu, J, Wei, T, Lei, J. Potential interaction between SARS-CoV-2 and thyroid: a review. Endocrinology. 2021;162:bqab004. doi:10.1210/endocr/bqab004.
Google Scholar | Crossref | Medline7. Garg, MK, Gopalakrishnan, M, Yadav, P, Misra, S. Endocrine involvement in COVID-19: mechanisms, clinical features, and implications for care. Indian J Endocrinol Metab. 2020;24:381-386. doi:10.4103/ijem.IJEM_440_20.
Google Scholar | Crossref | Medline8. Ruggeri, RM, Campennì, A, Deandreis, D, et al. SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. Expert Rev Clin Immunol. 2021;17:737-759. doi:10.1080/1744666X.2021.1932467.
Google Scholar | Crossref | Medline9. Bragazzi, NL, Hejly, A, Watad, A, Adawi, M, Amital, H, Shoenfeld, Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab. 2020;34:101412. doi:10.1016/j.beem.2020.101412.
Google Scholar | Crossref | Medline10. Watad, A, David, P, Brown, S, Shoenfeld, Y. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne). 2016;7:150. doi:10.3389/fendo.2016.00150.
Google Scholar | Crossref | Medline11. Teijaro, JR, Farber, DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195-197. doi:10.1038/s41577-021-00526-x.
Google Scholar | Crossref | Medline12. Olivieri, B, Betterle, C, Zanoni, G. Vaccinations and autoimmune diseases. Vaccines (Basel). 2021;9:815. doi:10.3390/vaccines9080815.
Google Scholar | Crossref | Medline13. Vojdani, A, Vojdani, E, Kharrazian, D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020;11:617089. doi:10.3389/fimmu.2020.617089.
Google Scholar | Crossref | Medline